{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:52:54Z","timestamp":1791874374105,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008414.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000}}],"reference-count":69,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008414.pub3","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T22:13:22Z","timestamp":1561068802000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Teuta","family":"Gjuladin-Hellon","sequence":"first","affiliation":[{"name":"University of Central Lancashire; School of Medicine; Preston Lancashire UK PR1 7BH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"University of Central Lancashire; School of Medicine; Preston Lancashire UK PR1 7BH"},{"name":"Blackpool Victoria Hospital; Families Division; Blackpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipporah","family":"Iheozor-Ejiofor","sequence":"additional","affiliation":[{"name":"University of Central Lancashire; School of Medicine; Preston Lancashire UK PR1 7BH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[{"name":"Sidra Medicine; PO Box 26999 Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008414.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2004.06.051","article-title":"Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease","volume":"127","author":"Ardizzone","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0016-5085(95)90059-4","article-title":"Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group","volume":"108","author":"Brignola","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008414.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1994.tb00158.x","article-title":"Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)","volume":"8","author":"Caprilli","year":"1994","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008414.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF02049478","article-title":"Prognostic factors for postoperative recurrence of Crohn's disease","volume":"39","author":"Caprilli","year":"1996","journal-title":"Diseases of the Colon & Rectum"},{"issue":"4","key":"10.1002\/14651858.CD008414.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2036.2003.01462.x","article-title":"Two mesalazine regimens in the prevention of the post-operative recurrence of Crohns disease: a pragmatic, double-blind randomized controlled trial","volume":"17","author":"Caprilli","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000199850","article-title":"Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial","volume":"42","author":"Ewe","year":"1989","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/978-3-642-85451-4_235","article-title":"Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double-blind study","volume":"82","author":"Ewe","year":"1977","journal-title":"Verhandlungen der Deutschen Gesellschaft fu\u0308r Innere Medizin"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01823251","article-title":"Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study--initial results","volume":"364","author":"Ewe","year":"1984","journal-title":"Langenbeck's Archives of Surgery"},{"issue":"3","key":"10.1002\/14651858.CD008414.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042737-199603000-00008","article-title":"Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"8","author":"Florent","year":"1996","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD008414.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","article-title":"Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial","volume":"127","author":"Hanauer","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"A1011","DOI":"10.1016\/S0016-5085(98)84115-2","article-title":"Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial","volume":"114","author":"Korelitz","year":"1998","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008414.pub3-BIB0012|cit12","first-page":"A480","article-title":"Double-blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5-ASA) for prevention of postoperative endoscopic recurrence in Crohn\u2019s disease","volume":"130","author":"Herfarth","year":"2006","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD008414.pub3-BIB0013|cit13","first-page":"1526","article-title":"Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease","volume":"55","author":"Herfarth","year":"2006","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0014|cit14","unstructured":"Muller R Herfarth H More Information on 2006 study published in Gut Email to Morris Gordon"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0016-5085(00)70208-3","article-title":"Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI","volume":"118","author":"Lochs","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0016-5085(95)90327-5","article-title":"Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease","volume":"109","author":"McLeod","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0017|cit17","unstructured":"NCT00946946 Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine clinicaltrials.gov\/ct2\/show\/NCT00946946"},{"issue":"6","key":"10.1002\/14651858.CD008414.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/gut.2009.194159","article-title":"Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial","volume":"59","author":"Reinisch","year":"2010","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008414.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/S1873-9946(13)60629-7","article-title":"Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow-up data of a randomised, double-blind, double-dummy, 1-year, multicentre trial","volume":"7","author":"Reinisch","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5","key":"10.1002\/14651858.CD008414.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S774","DOI":"10.1016\/S0016-5085(17)32685-9","article-title":"Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post-hoc analysis of a prospective randomized study","volume":"152","author":"Bodini","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/ajg.2013.287","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial","volume":"108","author":"Savarino","year":"2013","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008414.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365527809181743","article-title":"The long-term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial","volume":"13","author":"Wenckert","year":"1978","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0024|cit24","first-page":"249","article-title":"Can postoperative relapse of Crohn's disease be prevented?","volume":"96","author":"Dumois","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0025|cit25","first-page":"41","article-title":"Effectiveness of Azulfidine\/Salazopyrin in the postoperative prevention of recurrence in Crohn disease","volume":"19","author":"Ewe","year":"1981","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0026|cit26","unstructured":"ISRCTN84003996 Efficacy of mesalazine to prevent relapse in paediatric Crohn\u2019s disease isrctn.com\/ISRCTN84003996"},{"issue":"6","key":"10.1002\/14651858.CD008414.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0016-5085(97)70001-5","article-title":"Risk and significance of endoscopic\/radiological evidence of recurrent Crohn's disease","volume":"113","author":"McLeod","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0028|cit28","unstructured":"NCT00225810 A study comparing the acceptability of Pentasa\u00ae sachets versus Pentasa\u00ae tablets in children with Crohn's disease clinicaltrials.gov\/ct2\/show\/NCT00225810"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0029|cit29","unstructured":"NCT00245505 The effect on mucosal healing with Pentasa sachet in mild to moderate active \"Drug: Crohn's Disease\" clinicaltrials.gov\/ct2\/show\/NCT00245505"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0030|cit30","unstructured":"NCT00300118 Oral Budesonide vs. oral Mesalazine in active Crohn's disease (CD) clinicaltrials.gov\/ct2\/show\/NCT00300118"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0031|cit31","unstructured":"NCT01696942 Cimzia versus Mesalamine for Crohn's recurrence clinicaltrials.gov\/ct2\/show\/NCT01696942"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0016-5085(12)60977-9","article-title":"Early post-operative endoscopic recurrence in Crohn's disease patients: Data from a large prospective Italian multicenter cohort","volume":"1","author":"Orlando","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0033|cit33","unstructured":"NCT00976690 Comparison azathioprine to mesalazine for the prevention of postoperative recurrence in the Crohn disease (IMURELPOST) clinicaltrials.gov\/ct2\/show\/NCT00976690"},{"issue":"5","key":"10.1002\/14651858.CD008414.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12325-015-0206-4","article-title":"Release of 5-aminosalicylic Acid (5-ASA) from mesalamine formulations at various pH Levels","volume":"32","author":"Abinusawa","year":"2015","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD008414.pub3-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003715.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of medically induced remission in Crohns disease","author":"Akobeng","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008414.pub3-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003715.pub3","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease","author":"Akobeng","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8044","key":"10.1002\/14651858.CD008414.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","article-title":"Risk factors for surgery and postoperative recurrence in Crohn\u2019s disease","volume":"231","author":"Bernell","year":"2000","journal-title":"Annals of Surgery"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0039|cit39","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD008414.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohns disease: A meta-analysis adjusted for confounding variables","volume":"113","author":"Camma","year":"1997","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD008414.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"491-5","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008414.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease","volume":"11","author":"Franchis","year":"1997","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"435-9","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008414.pub3-BIB0044|cit44","first-page":"598","article-title":"Risk factors for postoperative recurrence of Crohn\u2019s disease with emphasis on surgical predictors","volume":"30","author":"Gklavas","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008414.pub3-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008414.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease","author":"Gordon","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7650","key":"10.1002\/14651858.CD008414.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0047|cit47","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions [Version 5.1.0]","author":"Higgins","year":"2011"},{"issue":"26","key":"10.1002\/14651858.CD008414.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"444-9","DOI":"10.1016\/0016-5085(81)90594-1","article-title":"Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine","volume":"81","author":"Ligumsky","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1038\/ajg.2017.394","article-title":"Surgical rates for Crohn\u2019s disease are decreasing: A population-based time trend analysis and validation study","volume":"112","author":"Ma","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008414.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008414.pub3-BIB0052|cit52","first-page":"692","article-title":"Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis","volume":"89","author":"Messori","year":"1994","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008414.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD008414.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.gastro.2016.10.038","article-title":"American gastroenterological association institute guideline on the management of Crohn\u2019s disease after surgical resection","volume":"152","author":"Nguyen","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0055|cit55","unstructured":"National Institute for Health and Care Excellence Crohn's disease: management (clinical guideline) nice.org.uk\/guidance\/cg152"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0056|cit56","unstructured":"National Institute for Health and Care Excellence Crohn's disease: management (NICE guideline NG129) nice.org.uk\/guidance\/ng129"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0058|cit58","first-page":"477","article-title":"5-Aminosalicylic acid in a slow-release preparation","volume":"32","author":"Rasmussen","year":"2015","journal-title":"Advances in Therapy"},{"issue":"8","key":"10.1002\/14651858.CD008414.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated recepter-y","volume":"201","author":"Rousseaux","year":"2005","journal-title":"Journal of Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008414.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohns disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/gut.51.2.152","article-title":"Crohn's disease recurrence can be prevented after ileal resection","volume":"5","author":"Rutgeerts","year":"2002","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD008414.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.13.4.278","article-title":"Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects","volume":"13","author":"Schroder","year":"1972","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0063|cit63","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0064|cit64","first-page":"297-9","article-title":"Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats","volume":"77","author":"Shafii","year":"1982","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008414.pub3-BIB0065|cit65","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0066|cit66","volume-title":"Methods for meta-analysis in medical research","author":"Sutton","year":"2000"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0067|cit67","first-page":"557","article-title":"Salazopyrin, a new sulfanilamide preparation","volume":"110","author":"Svartz N. Salazopyrin","year":"1942","journal-title":"Acta Medica Scandinavica"},{"key":"10.1002\/14651858.CD008414.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2009.09.009","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations","volume":"4","author":"Assche","year":"2010","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD008414.pub3-BIB0069|cit69","first-page":"632-5","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008414.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:20:06Z","timestamp":1628547606000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008414.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008414.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}